Stroke:COVID-19感染对缺血性卒中患者结局的影响

2021-08-30 MedSci原创 MedSci原创

与无COVID-19感染的缺血性卒中患者相比,COVID-19感染的缺血性卒中患者病情更严重,死亡率更高。然而,两组的功能结局相当。

近日,血管疾病领域权威杂志Stroke上发表了一篇研究文章,研究人员旨在评估伴有或不伴有2019冠状病毒病(COVID-19)感染的缺血性卒中患者的卒中严重程度、功能结局和死亡率是否不同。

研究人员在西班牙加泰罗尼亚进行了一项前瞻性、观察性、多中心队列研究。该研究从2020年3月中旬到5月中旬对受试者进行了连续招募。患者在48小时内发生急性缺血性卒中,之前的改良Rankin量表(mRS)评分为0至3。

研究人员收集了人口统计学数据、血管危险因素、既往mRS评分、美国国立卫生研究院卒中量表评分、再灌注治疗率和指标。该研究的主要终点是3个月时的功能结局。有利的结局取决于先前的mRS评分。次要结果是3个月时的死亡率。研究人员进行了mRS偏移和多变量分析。

研究人员评估了701名患者(平均年龄为72.3±13.3岁,60.5%为男性)和91名(13%)COVID-19患者。与没有COVID-19的患者相比,COVID-19患者的中位基线美国国立卫生研究院卒中量表评分更高(8[3-18] vs. 6[2-14],P=0.049)。在COVID-19和非COVID-19患者中,功能结局良好的患者比例分别为33.7%和47%。然而,经过多变量Logistic回归分析,COVID-19感染并没有增加不良功能结局的可能性。COVID-19患者的死亡率为39.3%,非COVID-19组的死亡率为16.1%。在多变量Logistic回归分析中,COVID-19感染是死亡的危险因素(风险比为3.14[95%CI为2.10–4.71];P<0.001)。

由此可见,与无COVID-19感染的缺血性卒中患者相比,COVID-19感染的缺血性卒中患者病情更严重,死亡率更高。然而,两组的功能结局相当。

原始出处:

Joan Martí-Fàbregas.et al.Impact of COVID-19 Infection on the Outcome of Patients With Ischemic Stroke.stroke.2021.https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.034883

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2010438, encodeId=79be201043837, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 02 20:44:27 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720409, encodeId=3ac41e2040964, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Aug 31 09:44:27 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806455, encodeId=4a4a1806455a4, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Aug 10 06:44:27 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893412, encodeId=5f091893412bf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 16 13:44:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480045, encodeId=2f9f148004575, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Sep 01 10:44:27 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013109, encodeId=6b8d101310974, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Tue Aug 31 09:23:05 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013066, encodeId=d194101306613, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Tue Aug 31 07:08:14 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026951, encodeId=e0d1102695107, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Aug 30 22:44:27 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2010438, encodeId=79be201043837, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 02 20:44:27 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720409, encodeId=3ac41e2040964, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Aug 31 09:44:27 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806455, encodeId=4a4a1806455a4, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Aug 10 06:44:27 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893412, encodeId=5f091893412bf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 16 13:44:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480045, encodeId=2f9f148004575, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Sep 01 10:44:27 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013109, encodeId=6b8d101310974, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Tue Aug 31 09:23:05 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013066, encodeId=d194101306613, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Tue Aug 31 07:08:14 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026951, encodeId=e0d1102695107, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Aug 30 22:44:27 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2010438, encodeId=79be201043837, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 02 20:44:27 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720409, encodeId=3ac41e2040964, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Aug 31 09:44:27 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806455, encodeId=4a4a1806455a4, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Aug 10 06:44:27 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893412, encodeId=5f091893412bf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 16 13:44:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480045, encodeId=2f9f148004575, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Sep 01 10:44:27 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013109, encodeId=6b8d101310974, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Tue Aug 31 09:23:05 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013066, encodeId=d194101306613, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Tue Aug 31 07:08:14 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026951, encodeId=e0d1102695107, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Aug 30 22:44:27 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2010438, encodeId=79be201043837, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 02 20:44:27 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720409, encodeId=3ac41e2040964, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Aug 31 09:44:27 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806455, encodeId=4a4a1806455a4, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Aug 10 06:44:27 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893412, encodeId=5f091893412bf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 16 13:44:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480045, encodeId=2f9f148004575, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Sep 01 10:44:27 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013109, encodeId=6b8d101310974, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Tue Aug 31 09:23:05 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013066, encodeId=d194101306613, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Tue Aug 31 07:08:14 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026951, encodeId=e0d1102695107, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Aug 30 22:44:27 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2010438, encodeId=79be201043837, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 02 20:44:27 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720409, encodeId=3ac41e2040964, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Aug 31 09:44:27 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806455, encodeId=4a4a1806455a4, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Aug 10 06:44:27 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893412, encodeId=5f091893412bf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 16 13:44:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480045, encodeId=2f9f148004575, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Sep 01 10:44:27 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013109, encodeId=6b8d101310974, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Tue Aug 31 09:23:05 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013066, encodeId=d194101306613, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Tue Aug 31 07:08:14 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026951, encodeId=e0d1102695107, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Aug 30 22:44:27 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2010438, encodeId=79be201043837, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 02 20:44:27 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720409, encodeId=3ac41e2040964, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Aug 31 09:44:27 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806455, encodeId=4a4a1806455a4, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Aug 10 06:44:27 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893412, encodeId=5f091893412bf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 16 13:44:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480045, encodeId=2f9f148004575, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Sep 01 10:44:27 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013109, encodeId=6b8d101310974, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Tue Aug 31 09:23:05 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013066, encodeId=d194101306613, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Tue Aug 31 07:08:14 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026951, encodeId=e0d1102695107, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Aug 30 22:44:27 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-08-31 谢尔比

    学习了学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2010438, encodeId=79be201043837, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 02 20:44:27 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720409, encodeId=3ac41e2040964, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Aug 31 09:44:27 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806455, encodeId=4a4a1806455a4, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Aug 10 06:44:27 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893412, encodeId=5f091893412bf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 16 13:44:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480045, encodeId=2f9f148004575, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Sep 01 10:44:27 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013109, encodeId=6b8d101310974, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Tue Aug 31 09:23:05 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013066, encodeId=d194101306613, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Tue Aug 31 07:08:14 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026951, encodeId=e0d1102695107, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Aug 30 22:44:27 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-08-31 smart Ren

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2010438, encodeId=79be201043837, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 02 20:44:27 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720409, encodeId=3ac41e2040964, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Aug 31 09:44:27 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806455, encodeId=4a4a1806455a4, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Aug 10 06:44:27 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893412, encodeId=5f091893412bf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 16 13:44:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480045, encodeId=2f9f148004575, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Sep 01 10:44:27 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013109, encodeId=6b8d101310974, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Tue Aug 31 09:23:05 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013066, encodeId=d194101306613, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Tue Aug 31 07:08:14 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026951, encodeId=e0d1102695107, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Aug 30 22:44:27 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-08-30 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

相关资讯

Stroke:血清锌含量与缺血性卒中发病率的关系

血清锌含量与缺血性卒中的发生率呈负相关,尤其是在女性中,表明低锌含量可能是缺血性卒中的危险因素。

FDA 批准卒中康复器械---迷走神经刺激Vivistim

卒中在中国每时每分都在发生,一旦发生如果 不及时治疗,患者轻则致残,重者死亡。无论卒中引发致残 和死亡都将给患者家庭和社会带来沉重负担 。

JAMA Neurology-天坛医院新发现:中度缺血性卒中,替卡格雷尔和阿司匹林联用,和单用阿司匹林效果无差异

天坛医院新发现:中度缺血性卒中,替卡格雷尔和阿司匹林联用,和单用阿司匹林效果无差异

JAMA Neurology-荟萃分析:大血管中风,及时取栓,时间就是生命

荟萃分析:大血管中风,及时取栓,时间就是生命

Stroke:肥胖与首次缺血性卒中风险取决于代谢综合征

在该队列中,肥胖不是缺血性卒中独立的危险因素,风险更多地取决于肥胖的代谢结局。

JAMA子刊:王拥军团队100万人数据提示,中国卒中患者的临床特征、管理和疗效

中风是我国死亡和成人残疾的主要原因,每年有超过1300万的中风和2390万的短暂性脑缺血发作(TIA)。